SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CBIS.OB Cannabis Science

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: xcentral12/23/2011 3:40:12 PM
2 Recommendations   of 27
 
Cannabis Science Extracts Kill Cancer Cells In Cancer Patients Being Treated Through Its Licensed Distributor Rockbrook

DENVER, Feb 22, 2011 (BUSINESS WIRE) -- Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells. Cannabis Science, in conjunction with Rockbrook, its Colorado-licensed dispensary, consulted with a variety of cancer patients who were seeking to inform themselves of the current peer reviewed scientific literature, regarding the historical use of cannabis to treat "tumors". Unlike most conventional cancer treatments, cannabis has an outstanding safety profile, and patients in states with medical marijuana laws are able to make an informed decision to legally try various cannabis preparations to determine what is most effective for their particular condition.
Some of these scientifically informed patients have chosen to self-administer Cannabis Science extracts supplied by Rockbrook to treat their own cancers. Cannabis Science is delighted that patients are reporting dramatic improvements in their conditions, including basal cell carcinoma, non-small cell lung cancer accompanied by COPD (chronic obstructive pulmonary disease), ovarian cancer, and glioma.

Please visit www.cannabisscience.com to view the "Breaking News" of the successful results and images of the self-administered cancer treatments.

For example, a patient with basal cell carcinoma used a topical formulation to dramatically and rapidly eliminate her obvious skin cancer. Meanwhile, patients with internal tumors used oral formulations for their treatment. We currently await more complete clinical evaluations of the patients' own reports of dramatic health improvements coincident with tumor shrinkage and disappearance.

Dr. Robert J. Melamede, the CEO and President of Cannabis Science Inc., stated, "We will pursue and acquire intra-state generated data to make these cancer medicines available to the public at large as rapidly as possible. To accomplish this goal, we will seek accelerated FDA approval. We are on the verge of a revolution in medicine. Cannabis is now returning to modern medicine for all the right reasons. State generated results give us a unique ability to acquire scientific and clinical data for cannabis-based cancer treatments. As previously announced, we will use our new laboratory facility to house analytical instrumentation, tissue culture, clean rooms and additional necessary equipment. This facility will meet or exceed all federal, state, and local requirements to allow for the necessary for FDA clinical trials."

Cannabis Science expects to hold a press conference soon to formally announce its cancer formulation progress and future plans for cancer treatments. Brand names for our new cancer treatment drugs are currently being vetted through the company attorney for future commercial use.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext